Background: Infants are vulnerable to zinc deficiency. Thus, abnormally low breast milk zinc levels cause transient neonatal zinc deficiency (TNZD) in breast-fed infants. TNZD has been considered to be rare because of a paucity of citations in the published literature. However, recent studies of affected mothers identified four missense mutations in the solute carrier family 30 member 2 gene (SLC30A2), which encodes the zinc transporter, ZnT2. Methods: Genetic analyses of SLC30A2/ZnT2 in three Japanese mothers secreting low-zinc milk (whose infants developed TNZD) were performed. The effects of identified mutations were examined in a cell-based assay. Furthermore, 31 single-nucleotide polymorphisms (SNPs) in SLC30A2/ZnT2 were evaluated for their potential involvement in low-zinc levels in milk. results: Each mother had a different novel heterozygous mutation in SLC30A2/ZnT2. One mutation reduced splicing efficiency of the SLC30A2/ZnT2 transcript, and all ZnT2 mutants were defective in zinc transport and were unstable in cells. Moreover, four SNPs caused a significant loss of zinc-transport activity, similar to that in disease-causing ZnT2 mutants. conclusion: Our results indicate that many SLC30A2/ZnT2 mutations cause or potentially cause TNZD. Genetic information concerning TNZD pathogenesis is limited, and our results suggest that the TNZD frequency may be higher than previously thought.
a pproximately 10% of all human proteins are thought to be zinc-binding, and zinc plays a pivotal role as a structural, catalytic, and signaling component of proteins in numerous physiological processes (1, 2) . Thus, zinc in breast milk is essential for the normal growth and development of infants (3, 4) . To meet infants' requirements, large amounts of zinc (1-3 mg/d) are secreted into breast milk during lactation, particularly in the first 3 mo after birth (5) (6) (7) . This is considerably higher than levels in the maternal serum (8) . A reduction in the level of breast milk zinc causes breast-fed infants to develop zinc deficiency, which presents with a broad range of defects, such as erythematous and erosive dermatitis, persistent diarrhea, hair loss, immune system dysfunction, and retardation in physical development (1, (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) . It is well known that the demand for zinc increases rapidly in thriving preterm infants (18, 19) , and thus a risk of zinc deficiency increases in preterm infants (20, 21) . However, symptomatic zinc deficiency has been found even in full-term infants, mostly because of inherited disorders.
Inherited zinc deficiency disorders in breast-fed full-term infants are classified into two types: acrodermatitis enteropathica (AE) (Online Mendelian Inheritance in Man (OMIM) 201100) and transient neonatal zinc deficiency (TNZD) (OMIM 608118) (1, 16, 17, 19, 22, 23) . AE is caused by the intestinal malabsorption of zinc, and as a result, infants still suffer from zinc deficiency after weaning. In contrast, TNZD is caused by low zinc concentrations in breast milk; thus, infants develop the symptoms of zinc deficiency only during breastfeeding. TNZD, as its name suggests, does not reoccur after weaning, and is therefore definitively different from AE. Mutations in zinc transporter genes have been identified to be responsible for each of these disorders (1, 16, 17) ; AE is caused by mutations in the solute carrier family 39 member 4 gene (SLC39A4) (also known as the Zrt-and Irt-like protein 4 gene (ZIP4)), while TNZD is caused by mutations in SLC30A2 (also known as the Zn transporter 2 gene (ZnT2)). ZIP4 is a zinc importer on the apical membrane of enterocytes and is essential for zinc absorption. Thus, disease-causing ZIP4 mutants lead to severe zinc deficiency. Conversely, ZnT2 mobilizes zinc into the secretory vesicles in mammary epithelial cells, which is thought to be released into the alveolar lumen, and then secreted into breast milk during lactation (5, 6 Articles TNZD in the literature, leading to the assumption that TNZD is extremely rare. Indeed, it has not been possible to define the frequency of this disorder (24) . However, in the past 8 y, at least 20 different Japanese case reports and abstracts have presented zinc deficiency in full-term infants caused by zinc-deficient breast milk (see Supplementary Table S1 online). Since the first finding of a missense mutation in SLC30A2/ZnT2 as a genetic cause of TNZD by Kelleher's group (10), one nonsense and four missense mutations have been identified in mothers secreting zinc-deficient breast milk, whose infants developed TNZD (12) (13) (14) (15) . In this article, we analyzed genomic DNA from three of the mothers included in the 20 Japanese reports and identified three novel loss-of-function SLC30A2/ZnT2 mutations. Moreover, we report here that four single-nucleotide polymorphisms (SNPs) in SLC30A2/ZnT2, which result in amino acid substitutions, cause ZnT2 to lose its zinc-transport activity. Our results provide crucial genetic information concerning TNZD pathogenesis in breast-fed infants.
RESULTS
Three Novel, Missense, Loss-of-Function, Heterozygous SLC30A2/ZnT2 Mutations For this study, we recruited three Japanese mothers who produced zinc-deficient breast milk and whose breast-fed infants suffered from severe zinc deficiency (see Supplementary  Table S2 online) . We analyzed all SLC30A2/ZnT2 exons and their flanking regions, including splice sites, in each mother and found three novel heterozygous missense mutations: c.838G>A at the end of exon 6 (with reference to the adenine of the start methionine as +1), c.935C>T (p.T312M) in exon 7, and c.1063G>C (p.E355Q) in exon 8 (see Figure 1a ,b and Supplementary Table S2 online). The c.838G>A mutation (a G to A substitution) conserved the consensus sequence of the splice site (human U2-type intron) (25) , but our reverse transcriptase-PCR analysis using ZnT2 cDNA constructs containing intron 6 (Figure 2a) indicated that it reduced the splicing efficiency of the ZnT2 transcript to almost one-fourth that of the wild-type (WT) sequence (Figure 2b) . Thus, the c.838G>A mutation results in reduced splicing efficiency of intron 6 and causes substitution p.G280R in the ZnT2 protein when intron 6 is spliced out.
Evaluation of Zinc-Transport Activity of the Three Novel ZnT2 Mutants Found in Japanese Mothers
We previously evaluated the defects of four TNZD missense ZnT2 mutations (two of which we identified (W152R and S296L) (13) and two of which were found by others (H54R and G87R) (10, 12) ), using genetically engineered mutant (ZnT1
) cells (13) . These cells show a zinc-sensitive phenotype, which is reversed by the stable expression of zinc-transport competent ZnT2. Similar to the well-established mutant BHK cell line (26) , our cell system is simple but useful for the examination of ZnT2 zinc-transport activity.
In the present study, the stable expression of G280R, T312M, and E355Q ZnT2 mutants failed to reverse the zinc-sensitive phenotype of ZnT1
ZnT4
−/− cells, suggesting that these mutants have impaired zinc-transport activity (Figure 3a) . Moreover, lack of zinc-transport activity in each mutant was confirmed using a fluorescent zinc-selective probe, Zinpyr-1 (27 (Figure 3c) . However, the expression of G280R, T312M, or E355Q ZnT2 mutants produced no increase in fluorescence intensity (Figure 3c) . Taken together, these findings indicate that all three mutations result in a lack of zinc-transport activity.
As detected in other previously reported TNZD-causing mutants (13) , the protein stability of these three ZnT2 mutants was significantly reduced (Figure 4a) . Moreover, immunoprecipitation analysis indicated that all three ZnT2 mutants can form dimers with WT ZnT2 (Figure 4b ), suggesting that they may impair the zinc-transport functions of WT ZnT2 in a dominant negative manner. These results indicate that SLC30A2/ZnT2 c.838G>A (p.G280R), c.935C>T (p.T312M), and c.1063G>C (p.E355Q) mutations cause loss-of-function and that haploinsufficiency or possible dominant negative effects result in low levels of zinc in the breast milk of affected mothers. Reduced splicing efficiencies may also contribute to pathogenesis in the c.838G>A mutation case.
Evaluation of SNPs on ZnT2 Zinc-Transport Function
We next evaluated the effects of SLC30A2/ZnT2 SNPs archived in the NCBI public database (http://www.ncbi.nlm.nih.gov/ snp) on ZnT2 zinc-transport activity to determine their potential involvement in the pathogenesis of TNZD. For a first evaluation, we randomly selected 31 SLC30A2/ZnT2 SNPs (all of which are shown to be minor alleles with frequencies up to 0.0036) (see Table 1 and Supplementary Table S3 online) that cause amino acid substitutions, and investigated their effects in viability assays using ZnT1
ZnT4
−/− cells. We found that four SNPs: rs148861822, c.542C>T (p.T181M); rs200520278, c.567C>A (p.N189K); rs201084300, c.698G>A (p.G233D); and rs377192955, c.1063G>A (p.E355K), failed to reverse the zinc-sensitive phenotype of ZnT1
−/− cells ( Table 1 and Figure 3b ). Flow cytometry analysis using Zinpyr-1 confirmed that these SNPs caused ZnT2 to lose zinc-transport activity (Figure 3d) , as in the case of TNZD-causing mutations (see Figure 3c ). These SNP mutants were all destabilized but could form dimers with WT ZnT2, similar to the TNZDcausing mutants described above (Figure 5a,b) . These results suggest that the four SNPs cause mothers to produce low-zinc breast milk and thus may be involved in TNZD pathogenesis in breast-fed infants. For another 27 SNP mutants, we found minimal defects in the cell viability assay (see Supplementary Table S3 online); therefore, these SNPs are unlikely to be involved in TNZD pathogenesis.
DISCUSSION
We are aware of at least 20 different reports and abstracts of transient zinc deficiency in full-term breast-fed infants published in the past 8 y (2007-2014) in Japan (see Supplementary Table S1 online). Moreover, 17 case reports of this condition were presented in domestic Japanese pediatrics and dermatology journals between 1981 and 2006 (28) . In all cases, zinc deficiency was attributed to low levels of zinc in the mother's breast milk, and symptoms were cured by zinc supplementation therapy and did not reoccur, which is typical for TNZD. Considering the paucity of TNZD-related publications in international journals (24) , the frequency of reported TNZD cases in Japan is of interest.
At present, over 50% of mothers in Japan are estimated to be exclusively breast-feeding their infants, which is a significant increase compared with the number in 2000 (about 40%) (29) . This may explain the recent increase in case reports, because the use of fortified formulas would mask the progression of TNZD and impact on apparent rates of TNZD. Additionally, pediatricians in Japan have recently learned that infant dermatitis is caused by zinc deficiency (30) . In most cases, TNZD is first suspected by low alkaline phosphatase activity (28, 31, 32) , which is routinely measured as a marker of liver function, and which is significantly dependent on zinc levels (33) . In infants where low alkaline phosphatase activity is detected, prompt measurement of zinc levels in the infant's serum and the mother's breast milk would be useful to facilitate early TNZD diagnosis.
In this study, we identified three novel, heterozygous SLC30A2/ZnT2 mutations in three affected Japanese mothers: c.838G>A in exon 6, c.935C>T in exon 7, and c.1063G>C in exon 8. The c.838G>A mutation reduced splicing efficiency, and also caused a G280R substitution, which resulted in the loss of zinc-transport activity. Moreover, T312M (c.935C>T) and E355Q (c.1063G>C) substitutions in SLC30A2/ZnT2 resulted in loss-of-function. The three novel TNZD-causing mutations presented here bring the total of TNZD-causing mutations identified to date to eight. There is, therefore, a larger variety, and a higher frequency, of TNZD-causing SLC30A2/ ZnT2 mutations than previously thought. Including the three cases in this study, all cases have reported heterozygous mutations in SLC30A2/ZnT2, except for one case with compound heterozygous mutations (13) , suggesting that TNZD is caused Articles Itsumura et al.
by haploinsufficiency or dominant negative mechanisms (10, (12) (13) (14) (15) . Consistent with affected mothers in previous reports (10, (12) (13) (14) (15) , the three affected mothers in this study produced breast milk with >70% reduced zinc levels (see Supplementary Table S2 online). Moreover, in the 20 recent reports and abstracts of TNZD in Japan, breast milk zinc levels were decreased by >60% in all mothers (see Supplementary  Table S1 online). However, comparison of zinc levels at the time of TNZD diagnosis with average normal zinc levels at (a) Evaluation of protein stability of G280R, T312M, and E355Q ZnT2 mutants. The expression levels of the wild-type (WT) (○) and each mutant (•) ZnT2 protein at each time point are shown. The collection of cells at 8 h was performed when the band intensity of the ZnT2 mutant protein was more than 50% at 2 h after cycloheximide treatment, compared with that at 0 h. Representative results of immunoblot analysis to monitor ZnT2 levels are shown (upper panel). Each value is the mean ± SD of triplicate experiments (lower panel). *A significant difference between levels of the WT and mutant ZnT2 proteins at each time point (*P < 0.05). Tubulin is shown as a loading control. (b) Evaluation of dimerization of G280R, T312M, and E355Q ZnT2 mutants. Tagged-ZnT2 WT or mutants were immunoprecipitated with antibodies against either the FLAG or HA epitopes. The immunoprecipitates were analyzed by immunoblotting using antibodies against the FLAG or HA tags. To estimate the amount of tagged ZnT2 WT and mutant proteins, 10% of each aliquot was subjected to immunoblot analysis (input panels). Calnexin (CNX) is shown as a loading control. The panels show representative results. 
Articles the corresponding time point during lactation is unreliable for setting a threshold for TNZD pathogenesis, because zinc levels in breast milk vary considerably among mothers (34, 35) . Furthermore, the onset or progression of disease is likely to depend on the health condition of the infant, including the zinc pool in the body. Thus, the relationship between zinc levels in breast milk and the onset and progression of TNZD needs to be more extensively investigated in future studies. In the 20 recent reports and abstracts, the maximum zinc level was 32 μg/dl at 5 mo (see Supplementary Table S1 online). Accordingly, a breast milk zinc content of 32 μg/dl or lower may be an index for the onset and progression of TNZD symptoms. Many SNPs have been identified in SLC30A2/ZnT2, and several have been well characterized; for example, two SNPs, rs35235055 (c.68T>C causing L23P) and rs35623192 (c.1018C>T causing R340C), have been proposed to compromise zinc secretion in breast milk (36) . In this study, we identified a further four SNPs that result in the loss of zinc-transport activity, suggesting their potential involvement in low levels of zinc secretion into milk. Of these, the position of rs377192955 (c.1063G>A causing E355K) is identical to that of the TNZD mutation found in patient 3 (E355Q), indicating that our SNP evaluation yielded reliable results. Because the molecular basis of ZnT2 functions has recently been revealed (37, 38) , detailed characterization of each SLC30A2/ZnT2 SNP and the relationship between each SLC30A2/ZnT2 SNP and the effects on zinc-transport activity would be beneficial for understanding TNZD pathogenesis. Further research is needed to determine if SLC30A2/ZnT2 SNPs can cause subtler or minor adverse effects.
In conclusion, infant zinc nutrition is of particular importance for healthy growth and development, and zinc levels in breast milk should be of primary concern. TNZD occurs through a deficiency of zinc levels in the mother's breast milk, which is controlled by ZnT2. Determination of the TNZD frequency is difficult to estimate because it may be masked by the use of fortified formulas. Moreover, there is a paucity of genetic information concerning TNZD pathogenesis (24) . However, our present results provide crucial genetic information about TNZD pathogenesis and indicate that the frequency of TNZD may be higher than previously thought. These findings provide helpful information to support the normal growth and development of breast-fed infants.
METHODS
Three full-term breast-fed infant patients were diagnosed with zinc deficiency by their pediatricians based on clinical presentations. Each infant showed low serum zinc levels and presented with symptoms of zinc deficiency at 1.5-5 mo. Zinc levels in the breast milk of all three mothers were also lower than the normal level expected during lactation (35, 39) ; however, their serum zinc levels were normal. Patient 1 was a full-term female (gestational age, 40 wk; birth weight, 2,630 g), who had been exclusively fed on breast milk from her mother. Dermatitis was present from 3 mo of age. Her serum zinc level was significantly low (13 μg/dl at 4 mo; normal level: 70-120 μg/ dl). At 4 mo, her mother's breast milk zinc level of 10 μg/dl was lower than the normal level of 80 ± 30 μg/dl at 4-6 mo. Clinical information for patients 2 and 3 has been reported in domestic Japanese journals (31, 32) , and the clinical data of all patients are summarized in Supplementary Table S2 online. All infants were given Polaprezinc (INN: (C 9 H 12 N 4 O 3 Zn) n , Zeria Pharmaceutical,Tokyo, Japan) oral zinc replacement therapy, which promptly eliminated symptoms.
Sequencing SLC30A2/ZnT2
Genomic DNA was isolated from the mothers' whole blood using a QIAamp DNA Blood Midi Kit (Qiagen, Hilden, Germany) or a NucleoSpin Blood Kit (Macherey-Nagel, Düren, Germany). All exons containing coding regions (including splice sites) of SLC30A2/ZnT2, and the sequence in and around the promoter regions of SLC30A2/ ZnT2 were directly sequenced in both directions, using fragments amplified from the isolated genomic DNA. Primer information is described in our previous study (13) .
Plasmid Construction, and Transient and Stable Transfection
ZnT2 cDNA expression plasmids containing intron 6, with G (WT) or A (mutant) at position c.838 at the 3′ end of exon 6 were constructed (see Figure 2a) . DT40 cells were transiently transfected with each plasmid as described previously (40) . For normalization of transient transfection efficiency, Renilla luciferase was used, and the activity ratio of each transfection was within 1.15. To evaluate zinc-transport activity in each ZnT2 mutant in stable transformants, we introduced mutations into ZnT2 cDNA as described previously (13) . DNA transfection to establish cells stably expressing WT ZnT2 or mutant ZnT2 was performed by electroporation as described previously (13, 40) .
Reverse Transcriptase-PCR Analysis
Total RNA was isolated from transiently transfected DT40 cells using Sepasol-RNA I Super (Nacalai Tesque, Kyoto, Japan). Reverse transcription was performed using ReverTra Ace (Toyobo, Osaka, Japan) and 1 µg total RNA as a template. PCR was performed using KOD Plus polymerase (Toyobo). The amplified products of spliced (281 bp) or unspliced (330 bp) forms of ZnT2 mRNA were electrophoresed on a 3% agarose gel and stained with ethidium bromide. For semiquantitative reverse transcriptase-PCR, products amplified after 33-35 cycles were quantified by densitometry using ImageQuant (GE Healthcare, Waukesha, WI). Primer sequences are listed in Supplementary Table S4 online. 
Evaluation of

ZnT4
−/− cells) were cultured as described previously (13, 40) . ZnT1 
−/− cells stably expressing zinc-transport competent ZnT2 can grow in a similar manner to parental cells. Thus, cell viability in high levels of extracellular zinc reflects the zinc-transport activity of ZnT2 (13, 40) . Cell viability was determined using the alamarBlue assay (Trek Diagnostic Systems, Westlake, OH). washing with phosphate-buffered saline containing 20 mmol/l ethylenediaminetetraacetic acid to remove extracellular zinc, the cells were resuspended in phosphate-buffered saline containing 1% bovine serum albumin and were subjected to flow cytometric analysis using a BD Accuri C6 flow cytometer (BD Biosciences, Ann Arbor, MI). Histograms were overlaid according to the log10 ratio increase of Zinpyr-1 fluorescence in zinc-supplemented (30 μmol/l ZnSO 4 ) conditions relative to normal conditions using Cytobank (http://www.cytobank.org/). The fluorescence intensity of Zinpyr-1 increases with zinc accumulation in vesicles and intracellular compartments mobilized from the cytosol and thus reflects the zinc-transport activity of ZnT2 proteins expressed in ZnT1 −/− MT −/− ZnT4 −/− cells in this study.
Evaluation of
Evaluation of Stability of Mutant ZnT2 Proteins
Cells expressing WT or mutant ZnT2 were treated with cycloheximide to block further protein synthesis and collected periodically over 4-8 h. The collection of cells at 8 h was performed when the band intensity of the ZnT2 mutant protein was more than 50% at 2 h after treatment, compared with that at 0 h. Total cell lysates were prepared from cells and subjected to immunoblotting to monitor ZnT2 levels as described previously (13) . The following antibodies were used: anti-ZnT2 (1:4,000 dilution) (13) or anti-tubulin (1:20,000; Sigma, St. Louis, MO). The ZnT2 band intensities are the averages of three independent experiments and are shown as the percentage of the intensity at 0 h (T 0 ) after normalization against tubulin at each time point. Fluoroimages were obtained using a LAS1000 Plus image analyzer 
